Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2002-07-22
2009-12-08
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C424S450000, C514S801000, C514S880000, C514S929000, C514S946000
Reexamination Certificate
active
07629384
ABSTRACT:
The application of L-arginine and its derivatives to the skin causes beneficial effects of wound healing, increasing erectile function and increased growth of hair when applied in sufficient quantity to the skin. A hostile biophysical agent may be combined with the L-arginine to increase its absorption into the skin. The desired concentrations of the hostile biophysical agent is increased when concentration of L-arginine is less than 20% of the concentration of the substance applied to maximize its effect.
REFERENCES:
patent: 4681897 (1987-07-01), Brand
patent: 4702903 (1987-10-01), Keefer
patent: 4732892 (1988-03-01), Sarpotdar et al.
patent: 4871839 (1989-10-01), Gibson
patent: 4950654 (1990-08-01), Horn et al.
patent: 4976952 (1990-12-01), Lang et al.
patent: 5028435 (1991-07-01), Katz et al.
patent: 5180743 (1993-01-01), Watanabe et al.
patent: 5254331 (1993-10-01), Mausner
patent: 5332758 (1994-07-01), Nakata et al.
patent: 5391550 (1995-02-01), Carniglia et al.
patent: 5405919 (1995-04-01), Keefer et al.
patent: 5428070 (1995-06-01), Cooke et al.
patent: 5439938 (1995-08-01), Snyder et al.
patent: 5476852 (1995-12-01), Cauwenbergh
patent: 5505958 (1996-04-01), Bello et al.
patent: 5538740 (1996-07-01), Abad
patent: 5543430 (1996-08-01), Kaesemeyer
patent: 5576351 (1996-11-01), Yoshimura et al.
patent: 5595753 (1997-01-01), Hechtman
patent: 5629002 (1997-05-01), Weuffen et al.
patent: 5632981 (1997-05-01), Saavedra et al.
patent: 5648101 (1997-07-01), Tawashi
patent: 5691423 (1997-11-01), Smith et al.
patent: 5698738 (1997-12-01), Garfield et al.
patent: 5714472 (1998-02-01), Gray et al.
patent: 5762963 (1998-06-01), Byas-Smith
patent: 5789442 (1998-08-01), Garfield et al.
patent: 5853768 (1998-12-01), Altadonna
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5895658 (1999-04-01), Fossel
patent: 5922332 (1999-07-01), Fossel
patent: 5925372 (1999-07-01), Berner et al.
patent: 5939094 (1999-08-01), Durif et al.
patent: 6036977 (2000-03-01), Drizen et al.
patent: 6103275 (2000-08-01), Seitz et al.
patent: 6117872 (2000-09-01), Maxwell et al.
patent: 6207713 (2001-03-01), Fossel
patent: 6242229 (2001-06-01), Pineau
patent: 6375672 (2002-04-01), Aksan et al.
patent: 6387081 (2002-05-01), Cooper
patent: 6448267 (2002-09-01), Anggard et al.
patent: 6451337 (2002-09-01), Smith et al.
patent: 6458841 (2002-10-01), Fossel
patent: 6511991 (2003-01-01), Hrabie et al.
patent: 6538033 (2003-03-01), Bing
patent: 6617337 (2003-09-01), Wilcox
patent: 6716436 (2004-04-01), Seguin
patent: 6747063 (2004-06-01), Adams et al.
patent: 2002/0015713 (2002-02-01), Murdock et al.
patent: 2002/0037854 (2002-03-01), Breton et al.
patent: 2002/0168325 (2002-11-01), Lerner et al.
patent: 2002/0168424 (2002-11-01), Shahinpoor et al.
patent: 10128910 (2002-12-01), None
patent: 0338291 (1989-10-01), None
patent: 0391342 (1990-10-01), None
patent: 1210933 (2002-06-01), None
patent: 1553063 (1967-11-01), None
patent: 5940 (1968-04-01), None
patent: 2602678 (1988-02-01), None
patent: 2740453 (1997-04-01), None
patent: 2810540 (2001-12-01), None
patent: 2094142 (1982-09-01), None
patent: 04-005231 (1992-09-01), None
patent: 6-247832 (1994-09-01), None
patent: 7-53336 (1995-02-01), None
patent: 09241156 (1997-09-01), None
patent: WO 88/06034 (1988-08-01), None
patent: WO 92/08705 (1992-05-01), None
patent: WO 9409750 (1994-05-01), None
patent: WO 95/13060 (1995-05-01), None
patent: 95/15147 (1995-06-01), None
patent: WO 95/15147 (1995-06-01), None
patent: WO 96/08966 (1995-09-01), None
patent: WO 96/14748 (1996-05-01), None
patent: WO 96/29988 (1996-10-01), None
patent: WO 97/16983 (1997-05-01), None
patent: WO 9739760 (1997-10-01), None
patent: WO 99/13717 (1999-03-01), None
patent: WO 00/03689 (2000-01-01), None
patent: WO 00/40215 (2000-07-01), None
patent: WO 00/54773 (2000-09-01), None
patent: WO 00/69469 (2000-11-01), None
patent: WO 01/45713 (2001-06-01), None
The Merck Index (12th Ed. 1996), p. 132.
Hirvonen et al., Effect of diffusion potential, osmosis and ion-exchange on transdermal drug delivery: theory and experiments, Journal of Controlled Release (1998), vol. 56, pp. 33-39.
International Search Report for International Application Serial No. PCT/US05/05726 dated Sep. 9, 2005.
International Search Report for International Application Serial No. PCT/US05/13228 dated Jul. 5, 2005.
International Search Report for International Application Serial No. PCT/US05/13230 dated Oct. 28, 2005.
International Search Report for International Application Serial No. PCT/US98/19429, international filing date Sep. 17, 1998.
Cooper, Eugene R., et al., “Penetration Enhancers” in: Transdermal Delivery of Drugs, Kydonieus and Berner (ed), CRC Press, Boca Raton, 1987, p. 57-62.
Riedel, Markus W., et al., “Different Mechanisms of L-Arginine Induced Dilation of Brain Arterioles in Normotensive and Hypertensive Rats”, CA: 122 (11) 130053t (Abstract).
Argiolas, A., et al., “Nitric Oxide is a Central Mediator of Penile Erection,”Neuropharmacology, vol. 11, pp. 1339-1344 (1994).
Birder et al., “Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder,”Chemical Abstracts(1998:548084), vol. 129, No. 255375.
Bunker, C.D., “Alteration in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia,”Correspondence, pp. 669.
DeBoer, E.M., “Does Topical Minoxidil Increase Skin Blood Flow? A Laser Doppler Flowmetry Study,”Acta Derm Venereo, vol. 68, pp. 271-274 (1988).
Dietz, N. M., “Is nitric oxide involved in cutaneous vasodilation during body heating in humans?”,J. Appl. Physiol., vol. 76, No. 5, pp. 2047-2053 (1994).
Garban, H., “Effect of aging on nitric oxide-mediated penile erection in rats,”Am. J. Physiol., vol. 268, pp. 467-475 (1995).
I-Sheng, T., “Evaluation of Vasulogenic Impotence Using Dynamic Penile Washout Test,”J. Formosan Med. Assoc., vol. 89, No. 11, pp. 992-996 (1990).
Kirkeby, H.J., “Role of the L-arginine
itric oxide pathway in relaxation of isolated human penile cavernous tissue and circumflex veins,”Acta Physiol Scand, vol. 149, pp. 385-392 (1993).
Klemp, P., “Subcutaneous Blood Flow in Early Male Patter Baldness,”J. Invest Dermatol, vol. 92, pp. 725-726 (1989).
Laan, E., et al., “Assessment of female sexual arousal: Response specificity and construct validity,”Psychophysiology, vol. 32, pp. 476-485 (1995).
Mathias, B. J. et al., “Topical Capsaicin for Chronic Neck Pain,”Am. J. Phys. Med. Rehabil., vol. 74, No. 1, pp. 39-44 (1995).
Moody, J.A., et al., “Effects of Long-Term Oral Administration of L-Arginine of the Rat Erectile Response,”American Urological Association, Inc., vol. 158, pp. 942-947 (1997).
Owen, J.A., et al., “Topical Nitroglycerin: A Potential Treatment for Impotence,”The Journal of Urology, vol. 141, pp. 546-548 (1989).
Pauly et al, Liposomes containing amino acids and peptides and proteins for skin care, Chemical Abstracts (1998), vol. 113, No. 65069.
Singh, S. et al., “Response to digital arteries to endothelium dependent and independent vasocilators in patients with Raynaud's phenomenon,”European Journal of Clinical Investigation, vol. 25, pp. 182-185 (1995).
Sonntag, M., et al., “Role of nitric oxide in local blood flow control in the anaesthetized dog,”European Journal of Physiology, pp. 194-199 (1992).
Tseng, L.F., et al., “Increase of nitric oxide production by L-arginine potentiates i.c.v. administered β-endorphin-induced antinociception in the mouse,”European Jouranal of Pharmacology, vol. 212, pp. 301-303 (1992).
Wang, R. et al., “Nitric Oxide Mediates Penile Erection in Cats,”The Journal of Urology, vol. 151, pp. 234-237 (1994).
Whitmore, S.E., et al, “Acute Effect of Topical Minoxidil on Digital Blood Flow in Patients with Raynaud's Phenomenon,”The Journal of Rheumatology, vol. 11, No. 1, pp. 50-54 (1
Pak John
Strategic Science & Technologies, LLC
Wolf Greenfield & Sacks P.C.
LandOfFree
Topical delivery of L-arginine to cause beneficial effects does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical delivery of L-arginine to cause beneficial effects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical delivery of L-arginine to cause beneficial effects will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149379